公开(公告)号：US11207308B2

公开(公告)日：2021-12-28

申请号：US16203182

申请日：2018-11-28

Applicant: PRILENIA NEUROTHERAPEUTICS LTD.

Inventor： Ross Nicholas Waters ,  Eva Susanna Holm Waters

IPC: A61K31/445 ,  A61K31/4375 ,  A61K31/451 ,  A61K31/4745

Abstract: This invention relates to novel pharmaceutical compositions comprising a therapeutically effective combination of a dopaminergic stabilizer known as Pridopidine, and an inhibitor of the vesicular monoamine transporter type 2 (VMAT) known as Tetrabenazine. The pharmaceutical compositions for use according to the invention are contemplated particularly useful for improving the symptomatic therapeutic effects, and for reducing the adverse effects, of Tetrabenazine in the treatment of movement disorders, and in articular movement disorders associated with Huntington's disease, Gilles de la Tourette's syndrome, or tardive dyskinesia.

公开(公告)号：US20200000785A1

公开(公告)日：2020-01-02

申请号：US16203182

申请日：2018-11-28

Applicant: Prilenia Neurotherapeutics Ltd.

Inventor： Ross Nicholas Waters ,  Eva Susanna Holm Waters

IPC: A61K31/445 ,  A61K31/4375 ,  A61K31/451 ,  A61K31/4745

Abstract: This invention relates to novel pharmaceutical compositions comprising a therapeutically effective combination of a dopaminergic stabilizer known as Pridopidine, and an inhibitor of the vesicular monoamine transporter type 2 (VMAT) known as Tetrabenazine. The pharmaceutical compositions for use according to the invention are contemplated particularly useful for improving the symptomatic therapeutic effects, and for reducing the adverse effects, of Tetrabenazine in the treatment of movement disorders, and in particular movement disorders associated with Huntington's disease, Gilles de la Tourette's syndrome, or tardive dyskinesia.